Malnutrition- inflammation- atherosclerosis syndrome in chronic kidney disease

Indian Journal of Clinical Biochemistry

Volumn 23, Issue 3, 2008, Pages 209-217

  Rao, Pragna ^a   Reddy, G C ^a   Kanagasabapathy, A S ^b  

^a Kamineni Institute of Medical Sciences   (India)

^b KAMINENI HOSPITALS   (India)

Author keywords

Atherosclerosis; Chronic kidney disease; Hemodialysis; Inflammation; Malnutrition; Syndrome

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; CYTOKINE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERMEDIATE DENSITY LIPOPROTEIN; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; ATHEROSCLEROSIS; CHRONIC KIDNEY DISEASE; ENDOTHELIAL DYSFUNCTION; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOALBUMINEMIA; INDIA; INFLAMMATION; KIDNEY DISEASE; LIPID BLOOD LEVEL; MALNUTRITION; MALNUTRITION INFLAMMATION ATHEROSCLEROSIS SYNDROME; NUTRIENT; PATHOPHYSIOLOGY; PATIENT MONITORING; PREVALENCE; PROTEIN CALORIE MALNUTRITION; PROTEIN DEGRADATION; REVIEW; UREMIA;

EID: 56849126937     PISSN: 09701915     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12291-008-0048-9     Document Type: Review

References (78)

1. . National Kidney Foundation, K/DOQI Clinical practice guidelines for chronic kidney disease: Evolution, classification and stratification. Am J Kidney Dis 2002; 39: s46-s75.
2. th ed, 2001;1221-22.
3. Agarwal SK, Dash SC, Irshad M, Raju S, Singh R, Pandey RM. Prevalence of Chronic Renal Failure in adults in Delhi, India. Nephrol Dial Transplant 2005; 20: 1638-42.
4. Lim VS. Thyroid function in patients with chronic renal failure. Proceedings of the second international congress on uremic research, Nasa, Japan 2001: Metabolic dysfunction in uremia. Am J Kidney Dis 2001;38:580-84.
5. Chung SH, Lindholm B, Lee HB. Influence of initial nutritional status on continuous ambulatory peritoneal dialysis patient survival. Perit Dial Int 2000; 20:19-26.
6. Stenvinkel P, Heimbürger O, Lindholm B, Kaysen GA, Bergström J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation, and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000; 15:953-60.
7. O' Sullivan AJ, Laroson JA, Chan M, Kelly JJ. Body composition and energy metabolism in chronic renal insufficiency. Am J Kidney Dis 2002; 39:369-75.
8. Roelfrema V, Clark RG. The growth hormone and insulin like growth factor axis. It's manipulation for the benefit of growth disorders in renal failure. J Am Soc Nephrol 2001; 12:1297-1306.
9. Goodman HM, Tai LR, Ray J, Cooke NE, Liebhaber SA. Human growth hormone variant produces insulin-like lipolytic responses in rat adipose tissue. Endocrinol 1991; 129:1779-83.
10. Bárány P, Eriksson LC, Hultcrantz R, Pettersson E, Bergström J. Serum ferritin and tissue iron in anemic dialysis patients. Miner Electrolyte Metab 1997; 23:273-6.
11. Mitch WE. Insights into the abnormalities of chronic renal disease attributed to malnutrition. Pathophysiology of chronic renal failure and complications. J Am Soc Nephrol 2002; 13:s22-27.
12. Odamaki M, Furuya R, Yoneyama T, Nishikino M, Hibi I, Miyaji K, et.al. Association of serum leptin concentration with weight loss in chronic hemodialysis patients. Am J Kidney Dis 1999; 33:361-8.
13. Ikizler TA, Wingard RL, Sun M, Harvell J, Parker RA, Hakim RM. Increased energy expenditure in hemodialysis patients. J Am Soc Nephrol 1996; 7:2646-53.
14. Yaker S, Liu J, Le Roith D. The growth hormone / insulin like growth factor spectrum: Implications for organ growth and development. Pediatric Nephrol 2000; 14: 544-9.
15. Jacob V, Le Carpentier JE, Salzano S, Naylor V, Wild G, Brown CB, et al. IGF-1, a marker of under nutrition in hemodialysis patients. Am J Clin Nutr 1990; 52:39-44.
16. Kopple JD, Swendseid ME, Shinaberger JH, Umezawa CY. The free and bound amino acid removed by hemodialysis. Tran Anm Soc Artif Inter Organs 1973 ; 19: 309-13.
17. Kopple JD. Pathophysiology of protein-energy wasting in chronic renal failure. J Nutr 1994; 129:s147-251.
18. Alfonso Martin Cueto Manzano. Hypoalbuminemia in dialysis patients. A malnutrition or an inflammatory marker? La Revista de Investigation Clinica 2001; 52: 152-8.
19. Moshage HJ, Janssen JA, Franssen JH, Hafkenscheid JC, Yap SH. Study of the molecular mechanisms of decreased liver synthesis of albumin in inflammation. J Clin Invest 1987; 79:1635-41.
20. Luger A, Kovarik J, Stummvoll HK, Urbanska A, Luger TA. Blood membrane interaction in hemodialysis leads to increased cytokine production. Kidney Int 1987; 32:84-8.
21. Ikzler TA, Hakin RM. Nutrition in end-stage renal disease. Kidney Int 1996; 50: 343-57.
22. Blackburn GL, Thornton PA. Nutritional assessment of the hospitalized patients. Med Clin North Am 1979; 63: 1103-15.
23. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al.The effects of dietary protein restriction and blood control on the progression of renal disease: Modification of diet in renal disease study group. N Engl J Med 1994; 330:877-84.
24. Mears A. Outcomes of continuous process improvement of a nutritional care program incorporating serum pre-albumin measurements. Nutrition 1996; 12: 479-84.
25. Chertow GM, Ackert K, Lew NL, Lazarus JM, Lowrie EG. Pre-albumin is as important as albumin in the nutritional assessment of hemodialysis patients. Kidney Int 2000; 58: 2512-7.
26. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, et al. Interleukin-6 predicts Hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32:107-14.
27. Qureshi AR, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimbürger O, Lindholm B, et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients.J Am Soc Nephrol 2002; 13 Suppl 1:S28-36.
28. Poole S, Bird TA, Selkirk S, Gaines-Das RE, Choudry Y, Stephenson SL, et al. Fate of injected interleukin-1 in rats: sequestration and degradation in the kidney. Cytokine 1990; 2:416-22.
29. Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, Moynot A, et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationship with activation markers of T-cells, B-cells, and monocytes. J Immunol 1995; 154:882-92.
30. Schindler R, Boenisch O, Fischer C, Frei U. Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol 2000; 53:452-9.
31. Miyata T, Hori O, Zhang J, Yan SD, Ferran L, Iida Y, et al. The receptor for advanced glycation end products(RAGE) is a central mediator of the interaction AGE-beta 2 microglobulin with human mononuclear phagocytes via an oxidant sensitive pathway: Implications for the pathogenesis of dialysis- related amyloidosis. Clin Invest 1996; 98: 1088-94.
32. Stenvinkel P. Inflammation in end-stage renal disease: could it be treated? Nephrol dial therapy 2002; 17:33-8.
33. Hotchkies RS, Karl IE. The Pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-50.
34. Bergstron J, Wang T, Limdholm B. Factors contributing to catabolism in end-stage renal disease patients. Mineral Eletrolyte metab 1998; 24:92-101.
35. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillère-Blandin C, Nguyen AT, Canteloup S, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161:2524-32.
36. Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among hemodialysis patients. Kidney Int. 2002; 62:620-26.
37. Schindler R, Linnenweber S, Schulze M, Oppermann M, Dinarello CA, Shaldon S, et al. Gene expression of Interleukin-1 beta during hemodialysis. Kidney Int 1993; 43:712-21.
38. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
39. Garibotto G, Russo R, Sofia A, Sala MR, Robaudo C, Moscatelli P, et al. Skeletal muscle protein synthesis and degradation in patients with chronic renal failure . Kidney Int 1994; 45:1432-9.
40. Guarnieri G, Toigo G, Fiotti N, Ciocchi B, Situlin R, Giansante C, et al. Mechanism of malnutrition in uremia. Kidney Int 1997; 62:s41-s44.
41. Marette A. Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Clin nutr Metab 2002; 5:377-83.
42. Charles A Dinarello. Interleukin-1: A pro-inflammatory cytokine, inflammation, basic principles and clinical correlates. 3rd ed, Lippincott Williams and Wilkins, Philadelphia, 1999.
43. Schindler R, Clark BD, Dinarello CA. Disassociation between interleukin-1β m RNA and protein synthesis in human peripheral blood mononuclear cells. J Biol Chem 1990; 265:10232-7.
44. Schindler R, Eichert F, Lepenies J, Frei U. Blood components influence cytokine induction by bacterial substances.Blood Purif 2001;19(4):380-7.
45. Miller LC, Isa S, Vannier E, Georgilis K, Steere AC, Dinarello CA. Live Borrelia burgdorferi preferentially activate IL-1β gene expression and protein synthesis over the interleukin-1 receptor antagonist. J Clin Invest 1992; 90:906-12.
46. Haichao Wang, Kevin J. Tracey. Tumor necrosis factor, Interleukin-6, Macrophage Migration Inflammatory Factor, and Macrophage Inflammatory protein-1 in inflammation. Inflammation: Basic principles and clinical correlates. 3rd ed, Lippincott Williams and Wilkins, Philadelphia, 1999.
47. Barton BE: IL-6. insights into novel biological activities. Clin Immunol Immunopathol 1997; 85:16-20.
48. Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, Mayer G. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003; 64:572-8.
49. Mastorakos G, Chrousos QP, Weber JS. Cachectin/tumor necrosis factor regulates hepatic acute phase gene expression. J Clin Invest 1986; 78:1349-54.
50. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Effects of interleukin-6 and leukemia inhibitory factor on the acute phase response and DNA synthesis in cultured rat hepatocytes. Lymphokine Cytokine Res 1991; 10:23-26.
51. Tracey KJ: Tumor necrosis factor (cachectin) in the biology of septic shock syndrome. Circ Shock 1991; 35:123-8.
52. Kumins NH, Hunt J, Gamelli RL, Filkins JP. Partial hepatectomy reduces the endotoxin-induced peak circulating levels of tumor necrosis factor in rats. Shock 1989; 338: 225-8.
53. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290:697-701.
54. Jungers P, Massy ZA, Nguyen Khoa T, Fumeron C, Labrunie M, Lacour B, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant 1997; 12:2597-602.
55. Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo interstitial disease. Lancet 1982; 2:1309-11.
56. Poole S, Bird TA, Selkirk S, Gaines-Das RE, Choudry Y, Stephenson SL, et al. Fate of injected interleukin-1 in rats: sequestration and degradation in the kidney. Cytokine 1990; 2:416-22.
57. Klein JB, Mc Leish KR, Ward RA. Transplantation, not dialysis corrects azotemia-dependent priming of the neutrophil oxidative burst. Am J Kidney Dis 1999; 33:483-91.
58. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidative stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-8.
59. Attman PO, Samuelsson O, Alanpovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-92.
60. Savdie E, Gibson JC, Crawford GA, Simons LA, Mahony JF. Impaired plasma triglyceride clearance as a feature of both uremic and post transplant triglyceridemia. Kidney Int 1980; 18:774-82.
61. Arnadottir M, Thyssel H, Dallongeville J. Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hyper triglyceridemia. Kidney Int 1995; 48:779-84.
62. Arnadottir M, Thysell H, Dallongeville J, Fruchart JC, Nilsson-Ehle P. Very low density lipoprotein of uremic patients is a poor substrate for bovine lipoprotein lipase in vitro. Metabolism 1996; 45:686-90.
63. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1995; 17:3542-56.
64. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation, in aortic wall cell culture. J Clin Invest 1995; 96: 2758-67.
65. Pruzanski W, Stefanski E, de Beer FC, de Beer MC, Ravandi A, Kuksis A. Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J Lipid Res 2000; 41: 1035-47.
66. 2-macroglobulin receptor. FEBS Lett 1993; 325:271-5.
67. Scanu AM. Lp(a) lipoprotein-coping with heterogeneity. New Eng J Med 2003; 349:2089-90.
68. Kronenberg F, Kuen E, Ritz E, Junker R, König P, Kraatz G, et al. Lipoprotein (a) serum concentrations and apolipoprotein (a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000; 11:105-15.
69. Gazzaruso C, Garzaniti A, Buscaglia P, Bonetti G, Falcone C, Fratino P, et al. Association between apolipoprotein (a) phenotypes and coronary heart disease at young age. J Am Coll Cardiol 1999; 33:157-63.
70. Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein (a) phenotypes predicts coronary artery disease in haemodialysis patients. J Am Soc Nephrol 1997; 8:1889-98.
71. Palmieri V, Celentano A, Roman MJ, de Simone G, Lewis MR, Best L, et al. Fibrinogen and preclinical echocardiographic target organ damage. The strong heart study. Hypertension 2001; 38:1068-74.
72. Retterstol L, Kierulf P, Pedersen JC, Bohn M, Bakken A, Erikssen J, et al. Plasma fibrinogen level and long-term prognosis in Norwegian middle-aged patients with previous myocardial infarction, A 10 year follows up study. J Intern Med 2001; 249:511-8.
73. Yamada K, Miyahara Y, Hamaguchi K, Nakayama M, Nakano H, Nozaki O, et al. Immuno histochemical study of human advanced glycosylation end products (AGE) in chronic renal failure. Clin Nephrol 1994; 42:354-61.
74. George A. Kaysen. Inflammation: Cause of vascular disease and malnutrition in dialysis patients. Semin Nephrol 2004; 24:431-6.
75. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94:2743-8.
76. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268:877-81.
77. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydral compounds enhance the binding of lipoprotein (a) to fibrin: A potential link between thrombosis, atherosclerosis, and sulfhydril compound metabolism. Proc Natl Acad Sci USA 1992; 89:10193-7.
78. Zadeh KK, Mehrotra R, Fouque D, Kopple JD. Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure. Semin Dial 2005 ;17(6):455-65.